Patent Grant
8399508
1. Field of the Invention
The present invention relates to topical formulations used for treating allergic and inflammatory diseases. More particularly, the present invention relates to formulations of olopatadine and their use for treating and/or preventing allergic or inflammatory disorders of the nose.
2. Description of the Related Art
As taught in U.S. Pat. Nos. 4,871,865 and 4,923,892, both assigned to Burroughs Wellcome Co. (“the Burroughs Wellcome Patents”), certain carboxylic acid derivatives of doxepin, including olopatadine (chemical name: Z-11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepine-2-acetic acid), have antihistamine and antiasthmatic activity. These two patents classify the carboxylic acid derivatives of doxepin as mast cell stabilizers with antihistaminic action because they are believed to inhibit the release of autacoids (i.e., histamine, serotonin, and the like) from mast cells and to inhibit directly histamine's effects on target tissues. The Burroughs Wellcome Patents teach various pharmaceutical formulations containing the carboxylic acid derivatives of doxepin, including nasal spray and ophthalmic formulations. See, for example, Col. 7, lines 7-26, and Examples 8 (H) and 8 (I) of the '865 patent.
U.S. Pat. No. 5,116,863, assigned to Kyowa Hakko Kogyo Co., Ltd., (“the Kyowa patent”), teaches that acetic acid derivatives of doxepin and, in particular, olopatadine, have anti-allergic and anti-inflammatory activity. Olopatadine is the cis form of the compound having the formula:
Medicament forms taught by the Kyowa patent for the acetic acid derivatives of doxepin include a wide range of acceptable carriers; however, only oral and injection administration forms are mentioned.
U.S. Pat. No. 5,641,805, assigned to Alcon Laboratories, Inc. and Kyowa Hakko Kogyo Co., Ltd., teaches topical ophthalmic formulations containing olopatadine for treating allergic eye diseases. According to the '805 patent, the topical formulations may be solutions, suspensions or gels. The formulations contain olopatadine, an isotonic agent, and “if required, a preservative, a buffering agent, a stabilizer, a viscous vehicle and the like.” See Col. 6, lines 30-43. “[P]olyvinyl alcohol, polyvinylpyrrolidone, polyacrylic acid or the like” are mentioned as the viscous vehicle. See Col. 6, lines 55-57.
PATANOL® (olopatadine hydrochloride ophthalmic solution) 0.1% is currently the only commercially available olopatadine product for ophthalmic use. According to its labelling information, it contains olopatadine hydrochloride equivalent to 0.1% olopatadine, 0.01% benzalkonium chloride, and unspecified amounts of sodium chloride, dibasic sodium phosphate, hydrochloric acid and/or sodium hydroxide (to adjust pH) and purified water.
Topical olopatadine formulations that are effective as products for treating allergic or inflammatory conditions in the nose are desirable.
The present invention provides topical olopatadine formulations that are effective as products for treating allergic or inflammatory disorders of the nose. The formulations of the present invention are aqueous solutions that comprise approximately 0.6% olopatadine. Despite their relatively high concentration of olopatadine, they do not contain any polymeric ingredient as a physical stability enhancing ingredient. The formulations contain a phosphate salt that permits the pH of the formulations to be maintained within the range 3.5-3.95 and that also aids in solubilizing the olopatadine drug in the presence of sodium chloride.
Among other factors, the present invention is based on the finding that stable, nasal spray, solution formulations of olopatadine can be prepared within a pH range of 3.5-3.95 using a phosphate buffer without the need for any polymeric ingredient to enhance the solubility or physical stability of the formulation.
Unless indicated otherwise, all component amounts are presented on a % (w/v) basis and all references to amounts of olopatadine are to olopatadine free base.
Olopatadine is a known compound that can be obtained by the methods disclosed in U.S. Pat. No. 5,116,863, the entire contents of which are hereby incorporated by reference in the present specification. The solution formulations of the present invention contain 0.54-0.62% olopatadine. Preferably, the solution formulations contain 0.6% olopatadine.
Olopatadine has both a carboxylic functional group (pKa1=4.18) and a tertiary amino group (pKa2=9.79). It exists in different ionic forms depending upon the pH of the solution. Olopatadine exists predominantly as a zwitterion in the pH range between the two pKa values with a negatively-charged carboxylic group and a positively-charged tertiary amino group. The iso-electric point of the olopatadine zwitterion is at pH 6.99. At a pH lower than pKa1, cationic olopatadine (with ionized tertiary amino group) is dominant. At a pH higher than pKa2, anionic olopatadine (with ionized carboxylic group) is dominant.
Acid-Base Equilibrium of Olopatadine
In many zwitterionic molecules, such as various amino acids, intra-molecular ionic interactions are not significant or do not exist. But the structure of olopatadine is such that intra-molecular interactions exist and are significant, possibly due to the distance and bonding angle between the oppositely charged functional groups. This interaction effectively reduces the ionic and dipole character of the molecule. The net effect of the intra-molecular interactions between the oppositely charged functional groups is the reduction of aqueous solubility of olopatadine. Olopatadine has the pH-solubility profile shown in
Generally, olopatadine will be added in the form of a pharmaceutically acceptable salt. Examples of the pharmaceutically acceptable salts of olopatadine include inorganic acid salts such as hydrochloride, hydrobromide, sulfate and phosphate; organic acid salts such as acetate, maleate, fumarate, tartrate and citrate; alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as magnesium salt and calcium salt; metal salts such as aluminum salt and zinc salt; and organic amine addition salts such as triethylamine addition salt (also known as tromethamine), morpholine addition salt and piperidine addition salt. The most preferred form of olopatadine for use in the solution compositions of the present invention is the hydrochloride salt of (Z)-11-(3-dimethylaminopropylidene)-6,11-dihydro-dibenz-[b,e]oxepin-2-acetic acid. When olopatadine is added to the compositions of the present invention in this salt form, 0.665% olopatadine hydrochloride is equivalent to 0.6% olopatadine free base. Preferably the compositions of the present invention comprise approximately 0.665% olopatadine hydrochloride.
In addition to olopatadine, the aqueous solution compositions of the present invention comprise a phosphate salt. The phosphate salt not only helps maintain the pH of the compositions within the targeted pH range of 3.5-3.95 by contributing to the buffer capacity of the compositions, but also helps solubilize olopatadine. Suitable phosphate salts for use in the compositions of the present invention include monobasic sodium phosphate, dibasic sodium phosphate, tribasic sodium phosphate, monobasic potassium phosphate, dibasic potassium phosphate, and tribasic potassium phosphate. The most preferred phosphate salt is dibasic sodium phosphate. The compositions of the present invention comprise an amount of phosphate salt equivalent (on an osmolality contribution basis) to 0.2-0.8%, preferably 0.3-0.7%, and most preferably 0.4-0.6% of dibasic sodium phosphate. In a preferred embodiment, the phosphate salt is dibasic sodium phosphate at a concentration of 0.4-0.6% (w/v). In a most preferred embodiment, the compositions contain 0.5% (w/v) dibasic sodium phosphate.
Phosphate buffer is commonly used in aqueous pharmaceutical compositions formulated near neutral pH. Phosphate buffer (pKa1=2.12, pKa2=7.1, pKa3=12.67) would not normally be chosen for an aqueous composition with a target pH range of 3.5-3.95 because it has low buffer capacity in that region. Other buffering agents are commonly used in aqueous pharmaceutical compositions, including acetate, citrate and borate buffers, but are not suitable for use in the topical nasal compositions of the present invention. Borate buffers are not suitable because they do not have any significant buffer capacity in the pH range 3.5-3.95. Though acetate and citrate buffers have buffer capacity in this region, they are not preferred because they have the potential to cause irritation to nasal mucosal tissues and undesirable taste and/or smell.
In addition to olopatadine and phosphate salt, the compositions of the present invention comprise sodium chloride as a tonicity-adjusting agent. The compositions contain sodium chloride in an amount sufficient to cause the final composition to have a nasally acceptable osmolality, preferably 240-350 mOsm/kg. Most preferably, the amount of sodium chloride in the compositions of the present invention is an amount sufficient to cause the compositions to have an osmolality of 260-330 mOsm/kg. In a preferred embodiment, the compositions contain 0.3-0.6% sodium chloride. In a more preferred embodiment, the compositions contain 0.35-0.55% sodium chloride, and in a most preferred embodiment, the compositions contain 0.35-0.45% sodium chloride.
The compositions of the present invention also contain a pharmaceutically acceptable pH-adjusting agent. Such pH-adjusting agents are known and include, but are not limited to, hydrochloric acid (HCl) and sodium hydroxide (NaOH). The compositions of the present invention preferably contain an amount of pH-adjusting agent sufficient to obtain a composition pH of 3.5-3.95, and more preferably, a pH of 3.6-3.8.
In one embodiment, the aqueous compositions of the present invention consist essentially of olopatadine, phosphate buffer, sodium chloride, a pH-adjusting agent, and water, and have a pH from 3.5-3.95. These compositions can be manufactured as sterile compositions and packaged in multi-dose, pressurized aerosol containers to avoid microbial contamination. In another embodiment, the aqueous compositions of the present invention contain a preservative and a chelating agent such that the compositions pass United States Pharmacopeia/National Formulary XXX criteria for antimicrobial effectiveness, and more preferably the Pharm. Eur. 5th Edition criteria for antimicrobial preservation (Pharm. Eur. B preservative effectiveness standard). Suitable preservatives include p-hydroxybenzoic acid ester, benzalkonium chloride, benzododecinium bromide, and the like. Suitable chelating agents include sodium edetate and the like. The most preferred preservative ingredient for use in the compositions of the present invention is benzalkonium chloride (“BAC”). The amount of benzalkonium chloride is preferably 0.005-0.015%, and more preferably 0.01%. The most preferred chelating agent is edetate disodium (“EDTA”). The amount of edetate disodium in the compositions of the present invention is preferably 0.005-0.015%, and more preferably 0.01%.
The aqueous solution compositions of the present invention do not contain a polymeric ingredient intended to enhance the solubility of olopatadine or the physical stability of the solution. For example, the compositions of the present invention do not contain polyvinylpyrrolidone, polystyrene sulfonic acid, polyvinyl alcohol, polyvinyl acrylic acid, hydroxypropylmethyl cellulose, sodium carboxymethyl cellulose or xanthan gum.
The compositions of the present invention are preferably packaged in opaque plastic containers. A preferred container is a high-density polyethylene container equipped with a nasal spray pump. Preferably, the package is designed to provide the spray characteristics described in commonly-assigned, co-pending, U.S. Patent Application Publication No. 2006/0110328, which is incorporated herein by reference.
The present invention also relates to a method of treating allergic rhinitis comprising topically administering to the nasal cavities a composition containing 0.6% olopatadine, phosphate buffer, sodium chloride, a pH-adjusting agent, and water. The compositions optionally contain one or more preservative ingredients. Preferably, the compositions are administered such that 1200 mcg of olopatadine (e.g., 600/mcg per 100 microliter spray×two sprays) is delivered to each nostril twice per day.
Certain embodiments of the invention are illustrated in the following examples.
a0.665% w/v olopatadine hydrochloride (665 mcg/100 microliter spray) is equivalent to 0.6% w/v olopatadine as base (600 mcg/100 microliter spray).
An exemplary compounding procedure for the nasal composition shown in Table 1 is described as below.
The effect of NaCl on the dissolution rate of olopatadine hydrochloride in water was determined. NaCl caused a significant reduction in the rate of dissolution of olopatadine. With addition of Na2HPO4, however, the dissolution of olopatadine was dramatically improved. The complete dissolution of 0.6% olopatadine solution without Na2HPO4 would take at least several hours assuming that the entire amount of olopatadine would eventually dissolve, but with Na2HPO4 it takes less than one minute. The results are shown in
The effect of NaCl, Na2HPO4, and mannitol on the dissolution rate of olopatadine hydrochloride in a nasal formulation containing 0.01% EDTA and 0.01% BAC was determined. The results are shown in
The effect of NaCl and Na2HPO4 concentrations on the dissolution rate of olopatadine hydrochloride in a nasal formulation containing 0.01% EDTA and 0.01% BAC was determined. The results are shown in
The two compositions shown in Table 2 below were prepared using the procedure described in Example 1 and visual observations of the compositions clarity were made at different points during the compounding procedure. The results are shown in Table 2.
The results for Formulation A show that it is a clear solution. The results for Formulation B show that despite the pH-solubility profile indicating 0.6% olopatadine should dissolve at pH 3.189, the olopatadine did not go into solution. These results demonstrate that, without phosphate buffer, 0.665% olopatadine hydrochloride did not completely dissolve in water in the presence of 0.7% NaCl at a pH as low as 3.6 using the compounding procedure described in Example 1.
Formulations 3A, 3B, and 3C shown in Table 3 were prepared without phosphate buffer and, despite extensive stirring, the olopatadine HCl was not completely solubilized. A portion of Formulation 3C was removed and phosphate buffer was added to form Formulation 3D. The results, summarized in Table 3, demonstrate that 0.665% olopatadine hydrochloride is not soluble in the tested nasal vehicle without a phosphate salt.
The composition of Example 1 above was prepared using four different sequences for the addition of ingredients. The four sequences are indicated in Table 4 in the “OA” (order of addition) columns. In each case, visual observations relating to the composition's clarity were recorded. The results are shown in Table 4. In all four cases (Formulations 4A-4D), at the end of the compounding procedure, the solutions were clear. (The solutions contained some extraneous fibrous particles that did not appear to be related to the drug or the formulation excipients and were likely attributable to laboratory equipment and glassware.)
bNA = not applicable
cPreferred method of manufacturing
The composition of Example 1 above was prepared but acetate, borate and citrate buffers, respectively, were substituted in place of the phosphate buffer. Visual observations regarding the clarity of each of the compositions were recorded and are shown in Table 5.
The compositions shown in Table 6 were prepared to examine (1) the effect of adding phosphate buffer to a composition containing olopatadine hydrochloride, BAC, EDTA, NaOH/HCl, and NaCl, (2) the effect of adding NaCl to a composition containing olopatadine, BAC, EDTA, NaOH/HCl, and (3) the effect of hot water on the dissolution of olopatadine in a composition comprising olopatadine, BAC, EDTA, NaCl and NaOH/HCl. In each case, visual observations concerning the clarity of the composition were recorded. The results are shown in Table 6.
The contribution of phosphate buffer to the buffer capacity of the composition of Example 1 was determined in a classical acid-base titration experiment. The results are shown in
The compositions (without phosphate buffer) shown below in Table 7A were prepared. Visual observations of the clarity of each composition were recorded as each composition was prepared. The results are shown in Table 7A.
Each of the compositions was then split. One portion of each was split again into three storage batches (“pre-filtration”) and the other portion was filtered through a 0.2 μM filter and then split into three storage batches (“post-filtration”). One of the storage batches of each set was stored at room temperature (˜22° C.), one in the refrigerator (˜4° C.), and one subjected to freeze-thaw cycling (one day in the freezer (˜−20° C.) and one day at room temperature, except over the weekends). Visual observations of the clarity of each sample of Formulation 7A (lacking BAC and EDTA) were recorded on the indicated days and the results were recorded. The results are shown in Tables 7B (pre-filtration) and 7C (post-filtration).
a Freeze-thaw cycle performed at 24 hour freeze/24 hour thaw except over weekends.
a Freeze-thaw cycle performed at 24 hour freeze/24 hour thaw except over weekends.
Ater nine days of observation, the post-filtration portion of Formulation 7A was split and a stir bar was added to each sample as a seeding agent (the stir bar was not rotating). Visual observations were recorded and the results are shown in Table 7 D.
a Freeze-thaw cycle performed at 24 hour freeze/24 hour thaw except over weekends.
b Initial observations were performed prior to addition of stir bars.
To other portions of composition 7A split after nine days of observation, excess olopatadine (a few small granules) was added to both the pre-filtration and post-filtration samples to determine if seeding would cause olopatadine to precipitate. Visual observations were recorded on the indicated days. The results are shown in Tables 7 E (unfiltered composition) and 7 F (filtered composition).
a Freeze-thaw cycle performed at 24 hour freeze/24 hour thaw except over weekends.
b Initial observations were performed prior to addition of excess olopatadine HCl.
a Freeze-thaw cycle performed at 24 hour freeze/24 hour thaw except over weekends.
b Initial observations were performed prior to addition of excess olopatadine HCl.
The stability of the composition “7B” (containing BAC and EDTA) was evaluated in the same fashion. The results are Shown in Tables 7G (Pre-filtration), 7H (Post-filtration), 7I (with stir bar added after 9 days), 7J (with excess olopatadine added after 9 days; pre-filtration), and 7K (with excess olopatadine added after 9 days; post-filtration).
a Freeze-thaw cycle performed at 24 hour freeze/24 hour thaw except over weekends.
a Freeze-thaw cycle performed at 24 hour freeze/24 hour thaw except over weekends.
a Freeze-thaw cycle performed at 24 hour freeze/24 hour thaw except over weekends.
b Initial observations were performed prior to addition of stir bars.
a Freeze-thaw cycle performed at 24 hour freeze/24 hour thaw except over weekends.
b Initial observations were performed prior to addition of excess olopatadine HCl.
a Freeze-thaw cycle performed at 24 hour freeze/24 hour thaw except over weekends.
b Initial observations were performed prior to addition of excess olopatadine HCl.
The compositions shown below in Table 8 were prepared using a compounding procedure similar to that described in Example 1. In all four cases, the NaCl was added after olopatadine during the compounding. All four compositions contained the equivalent of 110% of a 0.6% targeted concentration. Two of the compositions were formulated at a pH of 3.95 and two at 4.10 to test an extreme condition. The results are shown in Table 8.
The solution stability of the composition of Example 1 was examined by preparing variations of the composition at the pH's shown in Table 9 and subjecting the samples to 13 freeze-thaw cycles (same cycles as described in Example 11 above). Following the last cycle, the samples were stored in the freezer for approximately three weeks and then analyzed. The amount of olopatadine (pre- and post-filtration, 0.2 μM filter) was determined by HPLC assay as a percent of the labeled amount (0.6%). The samples were evaluated using four tests of solution clarity: “Nephelos” values were obtained using a turbidimeter (HF Scientific, Inc., Model No. DRT100B); “Clarity” was determined by visual observation using a method similar to the Ph. Eur. (5th Edition) method for evaluating solution clarity and degree of opalescence; “Precipitate” was determined by visual inspection and the presence of absence of precipitates was recorded; “Particles by Visual Observation” was determined by visual inspection under a light box where not more than 3 particles per 5 mL sample is considered “essentially particle free.” Osmolality and pH were also determined for each composition. The results are shown in Table 9. In four of the five cases (Samples 1-4), the compositions were clear solutions following the freeze-thaw cycling study, demonstrating the composition of Example 1 is a stable aqueous solution despite the absence of a polymeric physical stability-enhancing agent. The sample that did not remain a clear solution is Sample 5 (pH=4.45).
1Nephelos (Turbidity) of ≦3 NTU is considered clear solution as per Ph. Eur. (5th Ed.)
2Pre and post olopatadine assay, nephalos, clarity, precipitate, particles by visual observation, osmolality and pH were performed using clear solution from second test tube.
This invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its special or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.
This application is a continuation application of Ser. No. 11/703,373, filed Feb. 7, 2007, which is a continuation-in-part application of Ser. No. 11/079,996, filed Mar. 15, 2005, which is a continuation of Ser. No. 10/175,106, filed Jun. 19, 2002, which claims priority to U.S. Provisional Application Ser. No. 60/301,315, filed Jun. 27, 2001, all of which are incorporated herein by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4407791 | Stark | Oct 1983 | A |
| 4749700 | Wenig | Jun 1988 | A |
| 4778596 | Linder et al. | Oct 1988 | A |
| 4871865 | Lever, Jr. et al. | Oct 1989 | A |
| 4923892 | Lever, Jr. et al. | May 1990 | A |
| 5116863 | Oshima et al. | May 1992 | A |
| 5164194 | Hettche | Nov 1992 | A |
| 5443833 | Clark et al. | Aug 1995 | A |
| 5478565 | Geria | Dec 1995 | A |
| 5482706 | Igari et al. | Jan 1996 | A |
| 5641805 | Hayakawa et al. | Jun 1997 | A |
| 6054462 | Francois et al. | Apr 2000 | A |
| 6146622 | Castillo et al. | Nov 2000 | A |
| 6174914 | Yanni et al. | Jan 2001 | B1 |
| 6207684 | Aberg | Mar 2001 | B1 |
| 6274626 | Jonasse et al. | Aug 2001 | B1 |
| 6316483 | Haslwanter et al. | Nov 2001 | B1 |
| 6333044 | Santus et al. | Dec 2001 | B1 |
| 6995186 | Castillo et al. | Feb 2006 | B2 |
| 20010056093 | Yanni | Dec 2001 | A1 |
| 20060110328 | Cagle et al. | May 2006 | A1 |
| Number | Date | Country |
|---|---|---|
| 0048023 | Mar 1982 | EP |
| 0214779 | Mar 1987 | EP |
| 0235796 | Sep 1987 | EP |
| 61926 | Mar 1995 | JP |
| WO0003705 | Jan 2000 | WO |
| WO0121209 | Mar 2001 | WO |
| WO0121210 | Mar 2001 | WO |
| WO0135963 | May 2001 | WO |
| WO0154687 | Aug 2001 | WO |
| WO0230395 | Apr 2002 | WO |
| WO03002093 | Jan 2003 | WO |
| WO2004043470 | May 2004 | WO |
| Entry |
|---|
| Church, Martin K., Is Inhibition of Mast Cell Mediator Release Relevant to the Clinical Activity of Anti-Allergic Drugs?, Agents and Actions, 1986, pp. 288-293, vol. 18, 3/4. |
| Clegg, L.S., et al., Histamine Secretion From Human Skin Slices Induced by Anti-IgR and Artificial Secretagogues and the Effects of Sodium Cromoglycate and Salbutamol, Clinical Allergy, 1985, pp. 321-328, vol. 15. |
| Hamilton, S,A., et al., Comparison of a New Antihistaminic and Antiallergic Compound KW 4679 with Terfenadine and Placebo on Skin and Nasal Provocation in Atopic Individuals, Clinical and Experimental Allergy, 1994, pp. 955-959, vol. 24. |
| Ikeda, Katsuhisa, et al., Effects of Oxatomide and KW-4679 on Acetylcholine-Induced Responses in the Isolated Acini of Guinea Pig Nasal Glands. Int. Arch. Allergy Immunol., 1995, pp. 157-162, vol. 106. |
| Irani, Anne-Marie A., et al., Mast Cell Heterogeneity, Clinical and Experimental Allergy, 1989, pp. 143-155, vol. 19. |
| Kamei, C., et al.; Effect of (Z)-11-[3-(Dimethylamino) propylidene]-6, 11-dihydrodibenz[b,e]oxepin-2-acetic Acid Hydrochloride on Experimental Allergic Conjunctivitis and Rhinitis in Rats and Guinea Pigs, Arzneimittelforschung, 1995, pp. 1005-1008, vol. 45(9). |
| Kamei, Chiaki, et al., Effects of Certain Antiallergic Drugs on Experimental Conjunctivitis in Guinea Pigs, Atarashii Ganka, 1994, pp. 603-605, vol. 11(4) (abstract only). |
| Ohshima, Etsuo, et al., Synthesis and Antiallergic Activity of 11-(Aminoalkylidene)-6, 11, dihydrodibenz[b,e]oxepin Derivatives, J. Medicinal Chemistry, 1992, pp. 2074-2054, vol. 35(11). |
| Pearce, Cheryl A., et al., Effect of Disodium Cromoglycate on Antigen-Evoked Histamine Release From Human Skin, Clinical Exp. Immunol., 1974, pp. 437-440, vol. 17. |
| Pujara, et al., Effects of Formulation Variables on Nasal Epithelial Cell Integrity: Biochemical Evaluations, International J. of Pharmaceutics, 1995, pp. 197-203, vol. 114. |
| Sharif. N.A., et al., Characterization of the Ocular Antiallergic and Antihistaminic Effects of Olopatedine (AL-4943A), a Novel Drug for Treating Ocular Allergic Diseases, J. of Pharmacology and Experimental Therapeutics, 1996; pp. 1252-1261, vol. 278(3). |
| Sharif, N.A., et al., Olopatadine (AL-4943A): Pharmacological Profile of a Novel Anti-Histaminic/Anti-Allergic Drug for Use in Allergic Compounds, Investigative Ophthalmology & Visual Science, 1996, p. 1027, Vol, 37(3) (abstract only). |
| Siraganian, Reuben P., An Automated Continuous Flow System for the Extraction and Fluorometric Analysis of Histamine, Anal. Biochem., 1974, pp. 383-394, vol. 57. |
| Spitalny, L., et al., Olopatadine Ophthalmic Solution Decreases Itching and Redness Associated with Allergic Conjunctivitis, Investigative Ophthalmology & Visual Science, 1996, p. 593, vol. 37(3) (abstract only). |
| LB Schwartz, TF Huff. “Mast Cells.” The Lung, Scientific Foundation, 1991, Ch. 3.4.11, Raven Press, Ltd., New York, pp. 601-615. |
| Yanni; J.M., et al., The In Vitro and In Vivo Ocular Pharmacology of Olopatadine (AL-4943A), An Effective Anti-Allergic/Anti-Histamine Agent, Investigative Ophthalmology & Visual Science, 1996, p. 1028, vol. 37(3) (abstract only). |
| Zhang, Ming-Qiang, et al., Optically Active Analogues of Ebastine: Synthesis and Effect of Chirality on Their Antihistaminic Activity, Chirality, 1994, p. 631-641, vol. 6(8). |
| Astelin® Nasal Spray Product Insert, Jun. 7, 2002, 11 printed pages. |
| Ratner, P.H., et al., Safety and Efficacy of Olopatadine Hydrochloride Nasal Spray for the Treatment of Seasonal Allergic Rhinitis to Mount Cedar, Annals Allergy Asthsma Immunol., 2005, pp. 474-479, vol. 95. |
| Berge, S. M., et al., Pharmaceutical Salts, Journal of Pharmaceutical Science, Jan. 1977, pp. 1-19, vol. 66, No. 1. |
| Number | Date | Country | |
|---|---|---|---|
| 20110306659 A1 | Dec 2011 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60301315 | Jun 2001 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 11703373 | Feb 2007 | US |
| Child | 13173608 | US | |
| Parent | 10175106 | Jun 2002 | US |
| Child | 11079996 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 11079996 | Mar 2005 | US |
| Child | 11703373 | US |
